摘要
目的：研究、讨论来氟米特诱导和维持治疗Ⅳ型及V型狼疮肾炎（LN）的疗效以及安全性。方法：回顾分析在2010年2月至2012年2月来我院进行治疗的Ⅳ型及V型狼疮肾炎患者，随机抽取其中的60例作为研究对象，其中Ⅳ型患者42例，男患者为3例，女患者为39例，患者年龄18～56岁，平均年龄为35±12。而V型患者为18例，全部为女患者。患者年龄16-53岁，平均35±9岁。根据患者的体重和病情的轻重差异，使用来氟米特0．8—1．2mg·kg-1·d-1共3d-7d，然后逐渐减量达到0．4～0．8mg·kg-1·d-1。[1]结果：在诱导期，观察组A中，病情得到完全缓解的患者为15例，部分缓解的患者为14例，总有效率为90％，在观察组B中，病情的到完全缓解的患者为14例，部分缓解的患者为11例，总有效率为83．4％。两组比较差异显著p〈0．05，统计学有意义。结论：来氟米特能够狠有效的控制Ⅳ型度V型狼疮肾炎的病情。尤其是对V型狼疮肺炎有着明显的效果，并且副作用小，是目前治疗狼疮肺炎最为有效的一种新型免疫的抑制剂。
Objective：To study, discuss the effect of l eflunomide in induction and maintenance therapy of type IV and V lupus nephritis （ LN ） efficacy and safety. Methods：a retrospective analysis in 2010 February to 2012 February in our hospital for treatment of type IV and V lupus nephritis patients, randomly selected 60 cases as the research object, the type 42 Patients, 3 cases of male patients, female patients 39 cases, patients age 18- 56 years, mean age 35±12. Type V patients was 18 cases, all female patients. Patients aged 16-53 years, mean 35±9 years. According to the patient＇s weight and severity of differences, the use of leflunomide in 0. 8-1. 2mg ·kg-1 · d-1, 3d-7d, then gradually reduced to 0. 4-0. 8mg · Kg-1· d-1, Result：In the induction period, were observed in group A, got complete remission in patients with 15 cases, partial remission in patients of 14 cases, the total effective rate was 90% in the observation group, B, the disease until complete remission of the patients was 14 cases, partial remission in patients of 11 cases, the total effective rate was 83.4%. There was significant difference between two groups of P〈0.05, statistically meaningful. Conelnsion：Leflunomide is a safe and very effective control type IV and V in lupus nephritis patients. Especially for ofmembraneous lupus pneumonia has obvious effect, and the side effect is small, is currently the most effective treatment for lupus pneumonia, a novel immune inhibitor.
出处
《按摩与康复医学》
2012年第36期52-53,共2页
Chinese Manipulation and Rehabilitation Medicine
